Ciba-Geigy/Gipharmex Deursil
Executive Summary
Gallstone dissolver, approved Dec. 31, will be marketed in U.S. by Ciba-Geigy under licensing agreement with ltalian firm Gipharmex S.p.A. Ciba-Geigy said it assumes on Jan. 9 all rights to Deursil's approved NDA. Ciba-Geigy plans to launch Deursil 150 mg and 300 mg caps in the latter part of 1988. Deursil is indicated for "patients with radiolucent,-non-calcified, gallbladder stones" who carry high surgical risk or who refuse surgery.